[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-457970-105":59,"doc-detail-457970-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","large-scale-drug-screening-in-ipsc-derived-motor-neurons-from-sporadic-als-patients-identifies-a-potential-combinatorial-therapy","Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy","","Heterogeneous, predominantly sporadic neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) remain difficult to model at scale. This study established an iPSC library from 100 patients with sporadic ALS (SALS) and performed population-wide phenotypic screening. Patient-derived motor neurons recapitulated key SALS traits including reduced survival, accelerated neurite degeneration, transcriptional dysregulation, and riluzole pharmacological rescue. Drug screening of prior ALS-trial candidates showed most failed to mitigate neurodegeneration, while combinatorial testing highlighted baricitinib, memantine, and riluzole as a promising therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/large-scale-drug-screening-in-ipsc-derived-motor-neurons-from-sporadic-als-patients-identifies-a-potential-combinatorial-therapy/457970/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/large-scale-drug-screening-in-ipsc-derived-motor-neurons-from-sporadic-als-patients-identifies-a-potential-combinatorial-therapy/457970.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is modeling sporadic ALS (SALS) challenging?","Question",{"text":112,"@type":113},"SALS lacks pathophysiologically relevant animal or cell models. Existing approaches often rely on FALS gene mutation systems with nonphysiological expression and regulation, limiting translation to SALS.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study observe in iPSC-derived motor neurons from SALS patients?",{"text":117,"@type":113},"The motor neurons reproduced core SALS features, including reduced survival and accelerated neurite degeneration, alongside transcriptional dysregulation that correlated with donor survival and showed pharmacological rescue by riluzole.",{"name":119,"@type":110,"acceptedAnswer":120},"Which drug combination was identified as promising, and how was it determined?",{"text":121,"@type":113},"Combinatorial testing of effective drugs identified baricitinib, memantine, and riluzole as a promising therapeutic combination for SALS after large-scale screening and evaluation of drug efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},457970,1790789873,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","nature neuroscience  \nArticle [https://doi.org/10.1038/s41593-025-02118-7](https://doi.org/10.1038/s41593-025-02118-7)  \nLarge-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy  \nReceived: 25 May 2023  \nAccepted: 6 October 2025  \n\n| Published online: 24 November 2025 |\n| --- |\n|  Check for updates |\n\nChristopher R. Bye  1 , Elizabeth Qian  1, Katherine Lim1,  \nMaciej Daniszewski  2,3, Fleur C. Garton4, Bảo C. Trần-Lê1, Helena H. Liang2, Tian Lin4, John G. Lock  5, Duncan E. Crombie1, Steven Morgan  6, Yi Hu  1, Samantha K. Barton  1, Lucy M. Palmer  1, Elvan Djouma  7, Saritha Kodikara  8, Kim-Anh Lê Cao8, Thanuja Dharmadasa1, Anjali K. Henders4, Laura A. Ziser4, Matthew C. Kiernan9,10, Kevin Talbot  11, Merrilee Needham 12,13,14,  \nSusan Fletcher  13, Paul Talman  15, Susan Mathers  16, Naomi R. Wray 4,17, Alex W. Hewitt 2,18, Alice Pebay 2,3,19 & Bradley J. Turner 1,20   \nHeterogeneous and predominantly sporadic neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), remain highly challenging to model. Patient-derived induced pluripotent stem cell (iPSC) technologies offer great promise for these diseases; however, large-scale studies demonstrating accelerated neurodegeneration inpatients with sporadic disease are limited. Here we generated an iPSC library from 100 patients with sporadic ALS (SALS) and conducted population-wide phenotypic screening. Motor neurons derived from patients with SALS recapitulated key aspects of the disease, including reduced survival, accelerated neurite degeneration correlating with donor survival, transcriptional dysregulation and pharmacological rescue by riluzole. Screening of drugs previously tested in ALS clinical trials revealed that 97% failed to mitigate neurodegeneration, reflecting trial outcomesand validating theSALS model. Combinatorial testing of effective drugs identified baricitinib, memantine and riluzole asa promising therapeutic combination for SALS. These findings demonstrate that patient-derived iPSC models can recapitulate sporadic disease features, paving the way for anew generation of disease modeling and therapeutic discovery in ALS.  \nAmyotrophic lateral sclerosis (ALS) is a rapid and fatal disease defined pathologically by the selective degeneration of motor neurons in the brain and spinal cord. ALS results in progressive weakness and paralysis, impairing the ability to move, speak, swallow and breathe. Clinically heterogeneous, the causes of the disease are complex, multifactorial and poorly understood. Approximately 10% of patients present with a family history and/or harbor pathogenic variants in approximately 40 known ALS-causative genes, a condition referred to as familial ALS  \n(FALS). The remaining 90% of cases have an unknown etiology and are traditionally classified as sporadicALS (SALS). While important advancements have been made in identifying ALS-causative and risk factor genes, little progress has been achieved in determining the fundamental cause or disease mechanisms involved inSALS.  \nTherapeutic options for patients with SALS are limited. Riluzole remains the most widely prescribed treatment forALSand is the only approved medication to extend life1–3. Edaravone andAMX0035 have  \nA full list of affiliations appears at the end of the paper. [e-mail:](e-mail: chris.bye@florey.edu.au)[ chris.bye@florey.edu.au](e-mail: chris.bye@florey.edu.au); [bradley.turner@florey.edu.au](bradley.turner@florey.edu.au)  \nNature Neuroscience | Volume 29 | January 2026 |40–52 40  \nalso been granted regulatory approval in some countries; however, poor clinical evidence for their efficacy from real-world experiences or late-stage trials has limited the approval of edaravone in major jurisdictions and resulted in the removal of AMX0035 from the market. With current treatment and multidisciplinary care, the average life expectancy of persons diagnosed withALSis less than 2.3 years4.  \nA ma","cbCaidYfcDbyjDt1","https://ap.wps.com/l/cbCaidYfcDbyjDt1","pdf",7294139,33,"English","# Overview\n## ALS background and modeling challenges\n## iPSC library generation and population-wide screening\n## Drug screening outcomes and therapeutic combination","[{\"question\":\"Why is modeling sporadic ALS (SALS) challenging?\",\"answer\":\"SALS lacks pathophysiologically relevant animal or cell models. Existing approaches often rely on FALS gene mutation systems with nonphysiological expression and regulation, limiting translation to SALS.\"},{\"question\":\"What did the study observe in iPSC-derived motor neurons from SALS patients?\",\"answer\":\"The motor neurons reproduced core SALS features, including reduced survival and accelerated neurite degeneration, alongside transcriptional dysregulation that correlated with donor survival and showed pharmacological rescue by riluzole.\"},{\"question\":\"Which drug combination was identified as promising, and how was it determined?\",\"answer\":\"Combinatorial testing of effective drugs identified baricitinib, memantine, and riluzole as a promising therapeutic combination for SALS after large-scale screening and evaluation of drug efficacy.\"}]","Large-scale drug screening in iPSC-derived motor neurons from sporadic ALS patients identifies a potential combinatorial therapy | PDF",1790751031,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ca907f9d03113a5320947cb5a500bc4d.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/26c702e544cc743de20a4e09e08f947d.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/a1c308e4bbff7d4aac4f94c91981688c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/a16bf67b5ee9ecafe37aafc6c53725a5.webp",980,1301]